Novavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Vaccines can take years or even decades to develop. Our vaccine technology combines the power and speed of genetic engineering to efficiently produce protein-based nanoparticles.
These protein-based nanoparticles work with our proprietary Matrix-M™ adjuvant, which helps to enhance immunogenicity—ie, the ability of the vaccine to provoke an immune response in the body.
Our nanoparticle vaccine and adjuvant platform can be used to rapidly create investigational vaccines for existing and new pathogens, helping the world address important global health threats.